SLS

SELLAS Life Sciences Group, Inc. (SLS) | Rumor.io

SELLAS Life Sciences Group

SLS

Attention (50-day avg)0.55%

Attention rank (50-day avg)#34

Bullish sentiment (50-day avg)59%

Price to earnings ratio-46.4

Market capitalization2.3B

Earnings per share-0.22

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-26.9M

Social

What share of all stock conversation is about SLS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.56% -0.06	0.5% +0.06	0.49% +0	0.18% +0.07

Sep 30

The SLS trial for AML CR2/CRp2 patients has been ongoing for over 2 years, with the first interim analysis having been completed at 80th event occurrence.
The trial has shown significant efficacy, with more than 70% of patients still alive after 3 years plus of treatment.
The IDMC has approached an ethical threshold, with events/deaths coming from GPS functionality-cured patients, suggesting a halt for overwhelming efficacy.

Generated by AI

Sentiment

Of the messages about SLS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	70.04% +11.83	60.4% +6.86	55.79% -7.94	74.12% -6.37
Bearish	29.96% -11.83	39.6% -6.86	44.21% +7.94	25.88% +6.37

Bullish· Sep 29

The company's GPS technology is working fantastically well, and shareholders are sitting on a goldmine.
The stock has the potential for a 20x increase from its current price, making it a lucrative investment opportunity.
The weekly chart is indicating that the stock is close to a brutal move upwards, and the author is convinced of the company's success.

Bearish· Sep 29

The low volume in SLS may indicate a lack of interest or a wait-and-see approach among investors, potentially leading to a further decline in price.
The Orphan Drug, Rare Pediatric Disease, and Fast Track designations for Regal may indicate a reduced chance of a Super BAT for Regal, which could negatively impact SLS's stock price.
The prolonged period since the last patient enrolled in the Phase 3 trial may indicate that GPS will not meet its primary endpoint, which could further decrease the stock price of SLS.

Generated by AI

Topics

Of the messages about SLS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	40.89%	78%	46.71%	46.12%
Technical Analysis	46.31%	20.4%	41.63%	44.18%
Analysts	0%	0.2%	3.73%	4.95%
Controversies	0%	0.1%	4.65%	1.29%
Macro	0%	0%	3.02%	2.49%
Earnings	12.81%	1.3%	0.26%	0.97%

Earnings· Aug 15

Sellas Life Sciences Group, Inc. (SLS) reported Q2 earnings of -$0.130, beating analyst estimates by $0.050.
The company's earnings report was released, indicating improved performance compared to expectations.
Sellas Life Sciences' Q2 earnings were seen as a positive development, but some investors were looking for more substantial news or pipeline progress to drive the stock forward.

Announcements· Sep 26

Sellas Life Sciences Group, Inc. has partnered with IQVIA's communications agency, Simpson Healthcare, which specializes in scientific communications, publication planning, and medical education, indicating the company's transition from a developmental to a late-stage oncology stage.
The company's recent preclinical data on SLS009, a highly selective cyclin-dependent kinases 9 inhibitor, demonstrated a >6-fold increase in apoptosis and drove cell death past 67% in daraxonrasib-resistant PDAC models, showcasing the potential of CDK9 inhibition as a strategy to enhance RAS-directed therapy.
Sellas' hiring of Simpson Healthcare is a critical commercial move, allowing them to establish a robust commercial communication strategy to handle massive clinical breakthroughs, such as the recent preclinical data on SLS009, which has significant implications for the company's future and potential acquisitions.

Technical Analysis· Sep 17

The short interest in SLS is at a staggering 30% of the public float, with 57.9M shares short and 11.73 Days to Cover, making it a potential fuel for a gamma squeeze if the data delivers.
The SLS009 data presentation is highly anticipated, and a positive outcome could lead to a historic reckoning, with the short interest becoming fuel for a triumphant move in pharmaceutical history.
A push through $13.20 on rising volume could open the door to a fast move toward recent highs, but failure to hold $10.40 could trigger a slide back toward the low single digits as momentum fades.

Generated by AI

Community

Of the messages about SLS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	87.85%	89.29%	86.92%	80.02%
Newcomers	12.15%	10.71%	13.08%	19.98%

Regulars· Sep 30

The regulars are anticipating an update from SELLAS Life Sciences Group, Inc. on Thursday, and some are expressing frustration with the company's quiet period and the resulting market manipulation.
The efficacy of SELLAS' GPS treatment for AML patients is being discussed, with some arguing that it has turned a lethal cancer patient population into a chronic disease, and that the treatment's success has reached an overwhelming threshold.
The regulars are speculating about the possibility of SELLAS' share price moving significantly, with some mentioning the large call volume and the potential for a "tsunami" to wipe out short institutions.

Newcomers· Sep 29

New investors are taking a chance on SLS, despite past losses, hoping to start anew and possibly avoid late entry.
The company has been radio silent for 4 months, with no press releases or updates, causing concern among investors and patients.
Despite market dips and criticism, the treatment's success in extending patients' lives is being celebrated, with one user predicting nothing but another user joking about the treatment's potential.

Generated by AI

SLS009 increased apoptosis more than six-fold versus daraxonrasib in a MYC-amplified, daraxonrasib-resistant patient-derived pancreatic cancer organoid model - Combination of SLS009 and daraxonrasib further increased apoptosis to 36.5% and necrosis to 30.6%, supporting evaluation of CDK9 inhibition as a potential strategy to enhance RAS-directed therapy -SLS009 combined with BET inhibition demonstrated synergistic activity and sustained suppression of MYC, providing additional evidence of SLS009

4d agoYahoo Finance UK

SLS Stock Slips Overnight Ahead Of Pancreatic Cancer Conference — Retail Looks For Clues To SLS009’s Next Trial

Sellas said earlier laboratory work showed activity against pancreatic cancer cells resistant to RAS-targeting drugs.

6d agoYahoo Finance

Sellas Life Sciences: Valued For Perfection, REGAL Trial Success Probability Priced In

SELLAS Life Sciences is rated Hold, with a $9.25 price target, as the current valuation reflects REGAL trial success probability. Read more on SLS stock here.

8d agoSeeking Alpha

SELLAS Life Sciences Group (SLS) Lands 3 AACR Abstracts For SLS009 Pancreatic Cancer Data

SELLAS Life Sciences Group (NasdaqCM:SLS) will present new preclinical data on SLS009 in pancreatic ductal adenocarcinoma at the 2026 AACR Conference. Three abstracts on SLS009 have been accepted, focusing on its mechanism of action and activity in KRAS mutant pancreatic cancer models. The research is being carried out with a respected academic institution and adds detail on SLS009 within SELLAS Life Sciences Group's preclinical pipeline. Interest in SELLAS Life Sciences Group reflects a...

27d agoYahoo Finance

SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer

- Three posters to highlight preclinical activity of SLS009 (tambiciclib) across patient-derived KRAS mutant organoid models of pancreatic cancer – - Studies conducted in collaboration with the University of Wisconsin School of Medicine and Public Health - NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer

27d agoYahoo Finance

Also Discussed

Investors talking about SLS also mention

#	Name	Attention
1	Legacy Education Inc.LGCY	0%new
2	Greenwich LifeSciences, Inc.GLSI	0%0
3	Cingulate Inc.CING	0%new
4	Abivax SAABVX	0.01%-0.01
5	Viveve Medical Inc.VIVE	0%0
6	OBLN - Obalon Therapeutics, Inc.	——
7	Os Therapies Inc.OSTX	0.1%+0.07
8	Alpha Tau Medical Ltd.DRTS	0%+0
9	SeaStar Medical Holding CorporationICU	0.02%+0.02
10	ImmunityBio Inc.IBRX	0.28%-0.06

SELLAS Life Sciences Group, Inc.

Healthcare
Biotechnology

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on developing novel therapies for cancer. SELLAS Life Sciences Group, Inc. concentrates on immunotherapeutic and targeted oncology programs designed to address a broad range of hematologic and solid tumor indications. Its current pipeline includes product candidates aimed at cancers such as acute myeloid leukemia, reflecting its emphasis on disease areas with significant unmet medical need. The company’s work centers on advancing clinical-stage assets through research and development, with a business model built around innovative cancer treatment platforms rather than commercialized consumer products. Headquartered in New York, SELLAS Life Sciences Group, Inc. plays a role in the biotechnology market as a specialist developer of experimental oncology therapies.

Website

Location

7 Times Square

New York, NY, 10036

United States

Social

What share of all stock conversation is about SLS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.56% -0.06	0.5% +0.06	0.49% +0	0.18% +0.07

Sep 30

The SLS trial for AML CR2/CRp2 patients has been ongoing for over 2 years, with the first interim analysis having been completed at 80th event occurrence.
The trial has shown significant efficacy, with more than 70% of patients still alive after 3 years plus of treatment.
The IDMC has approached an ethical threshold, with events/deaths coming from GPS functionality-cured patients, suggesting a halt for overwhelming efficacy.

Generated by AI

Sentiment

Of the messages about SLS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	70.04% +11.83	60.4% +6.86	55.79% -7.94	74.12% -6.37
Bearish	29.96% -11.83	39.6% -6.86	44.21% +7.94	25.88% +6.37

Bullish· Sep 29

The company's GPS technology is working fantastically well, and shareholders are sitting on a goldmine.
The stock has the potential for a 20x increase from its current price, making it a lucrative investment opportunity.
The weekly chart is indicating that the stock is close to a brutal move upwards, and the author is convinced of the company's success.

Bearish· Sep 29

The low volume in SLS may indicate a lack of interest or a wait-and-see approach among investors, potentially leading to a further decline in price.
The Orphan Drug, Rare Pediatric Disease, and Fast Track designations for Regal may indicate a reduced chance of a Super BAT for Regal, which could negatively impact SLS's stock price.
The prolonged period since the last patient enrolled in the Phase 3 trial may indicate that GPS will not meet its primary endpoint, which could further decrease the stock price of SLS.

Generated by AI

Topics

Of the messages about SLS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	40.89%	78%	46.71%	46.12%
Technical Analysis	46.31%	20.4%	41.63%	44.18%
Analysts	0%	0.2%	3.73%	4.95%
Controversies	0%	0.1%	4.65%	1.29%
Macro	0%	0%	3.02%	2.49%
Earnings	12.81%	1.3%	0.26%	0.97%

Earnings· Aug 15

Sellas Life Sciences Group, Inc. (SLS) reported Q2 earnings of -$0.130, beating analyst estimates by $0.050.
The company's earnings report was released, indicating improved performance compared to expectations.
Sellas Life Sciences' Q2 earnings were seen as a positive development, but some investors were looking for more substantial news or pipeline progress to drive the stock forward.

Announcements· Sep 26

Sellas Life Sciences Group, Inc. has partnered with IQVIA's communications agency, Simpson Healthcare, which specializes in scientific communications, publication planning, and medical education, indicating the company's transition from a developmental to a late-stage oncology stage.
The company's recent preclinical data on SLS009, a highly selective cyclin-dependent kinases 9 inhibitor, demonstrated a >6-fold increase in apoptosis and drove cell death past 67% in daraxonrasib-resistant PDAC models, showcasing the potential of CDK9 inhibition as a strategy to enhance RAS-directed therapy.
Sellas' hiring of Simpson Healthcare is a critical commercial move, allowing them to establish a robust commercial communication strategy to handle massive clinical breakthroughs, such as the recent preclinical data on SLS009, which has significant implications for the company's future and potential acquisitions.

Technical Analysis· Sep 17

The short interest in SLS is at a staggering 30% of the public float, with 57.9M shares short and 11.73 Days to Cover, making it a potential fuel for a gamma squeeze if the data delivers.
The SLS009 data presentation is highly anticipated, and a positive outcome could lead to a historic reckoning, with the short interest becoming fuel for a triumphant move in pharmaceutical history.
A push through $13.20 on rising volume could open the door to a fast move toward recent highs, but failure to hold $10.40 could trigger a slide back toward the low single digits as momentum fades.

Generated by AI

Community

Of the messages about SLS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	87.85%	89.29%	86.92%	80.02%
Newcomers	12.15%	10.71%	13.08%	19.98%

Regulars· Sep 30

The regulars are anticipating an update from SELLAS Life Sciences Group, Inc. on Thursday, and some are expressing frustration with the company's quiet period and the resulting market manipulation.
The efficacy of SELLAS' GPS treatment for AML patients is being discussed, with some arguing that it has turned a lethal cancer patient population into a chronic disease, and that the treatment's success has reached an overwhelming threshold.
The regulars are speculating about the possibility of SELLAS' share price moving significantly, with some mentioning the large call volume and the potential for a "tsunami" to wipe out short institutions.

Newcomers· Sep 29

New investors are taking a chance on SLS, despite past losses, hoping to start anew and possibly avoid late entry.
The company has been radio silent for 4 months, with no press releases or updates, causing concern among investors and patients.
Despite market dips and criticism, the treatment's success in extending patients' lives is being celebrated, with one user predicting nothing but another user joking about the treatment's potential.

Generated by AI

SELLAS Life Sciences Group

Social

Sep 30

Bullish· Sep 29

Bearish· Sep 29

Earnings· Aug 15

Announcements· Sep 26

Technical Analysis· Sep 17

Regulars· Sep 30

Newcomers· Sep 29

SELLAS Life Sciences Group (SLS) Could Be Fully Priced After Fresh SLS009 Pancreatic Data

SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer

SLS Stock Slips Overnight Ahead Of Pancreatic Cancer Conference — Retail Looks For Clues To SLS009’s Next Trial

Sellas Life Sciences: Valued For Perfection, REGAL Trial Success Probability Priced In

SELLAS Life Sciences Group (SLS) Lands 3 AACR Abstracts For SLS009 Pancreatic Cancer Data

SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer

Also Discussed

SELLAS Life Sciences Group, Inc.

Company Information

Location

SELLAS Life Sciences Group (SLS) Could Be Fully Priced After Fresh SLS009 Pancreatic Data

SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer

SLS Stock Slips Overnight Ahead Of Pancreatic Cancer Conference — Retail Looks For Clues To SLS009’s Next Trial

Sellas Life Sciences: Valued For Perfection, REGAL Trial Success Probability Priced In

SELLAS Life Sciences Group (SLS) Lands 3 AACR Abstracts For SLS009 Pancreatic Cancer Data

SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer

Also Discussed

Social

Sep 30

Bullish· Sep 29

Bearish· Sep 29

Earnings· Aug 15

Announcements· Sep 26

Technical Analysis· Sep 17

Regulars· Sep 30

Newcomers· Sep 29